From: Update of the organoprotective properties of xenon and argon: from bench to beside
Xenon | ||||
---|---|---|---|---|
Author | Effects revealed in human | Effects revealed in in vivo | Effects revealed in in vitro | Organprotection |
Yakamura and Harris [31] | Non-competitive blockade of NMDA receptors and nACH (N-acetyl-choline receptors nACH) | |||
Li et al. [32] | mitoKATPchannel | Heart | ||
Gruss et al. [33] | Activation of two-pore-domain K+channel (TREK-1) | Brain | ||
Ma et al. [34] | Hypoxia inducible factor 1α↑ EPO ↑, VEGF↑ mTOR expression↑ | Renal | ||
Zhao et al. [35] | IGF-1↑, HIF 1α↑, NF-κB↓ | Renal | ||
Dinse et al. [36] | Blocks AMPA. receptor & kainate receptors | Brain | ||
Bantel et al. [37] | KATP – Opener | Brain | ||
Protein kinase C (PKC)-ε, EKR1/2 P38MAPK, HSP 27, JNK | Heart | |||
Luo et al. [41] | PI3K Signaling | Brain | ||
Banks et al. [42], | Competitive NMDA receptor inhibition | Brain | ||
Harris et al. [43], | Competitive NMDA receptor inhibition Activation of TREK-1 channels | Brain | ||
Franks et al. [44] | Inhibition of NMDA receptor | Brain |